These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27812078)

  • 1. Classification of non-insulin glucose lowering drugs.
    Kalra S
    J Pak Med Assoc; 2016 Nov; 66(11):1497-1498. PubMed ID: 27812078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiating oral anti diabetic drug: alternatives to metformin.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 Apr; 65(4):440-1. PubMed ID: 25976586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.
    Chi C; Snaith J; Gunton JE
    Heart Lung Circ; 2017 Nov; 26(11):1133-1141. PubMed ID: 28473214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
    Bonnet F; Scheen AJ
    Diabetes Metab; 2017 Sep; 43(4):299-313. PubMed ID: 28522196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.
    Lo MC; Lansang MC
    Am J Ther; 2013; 20(6):638-53. PubMed ID: 20838206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
    Blevins T
    Expert Opin Drug Saf; 2015 May; 14(5):789-93. PubMed ID: 25789798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments and emerging therapies for type 2 diabetes mellitus.
    Evans AJ; Krentz AJ
    Drugs R D; 1999 Aug; 2(2):75-94. PubMed ID: 10820647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of approved pioglitazone combinations for type 2 diabetes.
    Forst T; Hanefeld M; Pfützner A
    Expert Opin Pharmacother; 2011 Jul; 12(10):1571-84. PubMed ID: 21639813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control.
    Scheen AJ; Esser N; Paquot N
    Diabetes Metab; 2015 Jun; 41(3):183-94. PubMed ID: 25794703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of type 2 diabetes].
    Meier JJ
    Internist (Berl); 2016 Feb; 57(2):153-65. PubMed ID: 26795946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.